Antibody–drug conjugates (ADCs)—new targeted therapies Georgios Papakonstantinou editorial 26 November 2013 Pages: 223 - 224
Neurooncology: current findings and challenges for the future Silvia Hofer editorial 22 June 2013 Pages: 225 - 226
ASCO 2013: news in early-stage and advanced breast cancer Günther G. StegerRupert Bartsch short review 26 November 2013 Pages: 227 - 232
Recent developments in the palliative treatment of breast cancer: ASCO 2013 Edgar PetruTina IdrisEva Schest special report 29 October 2013 Pages: 233 - 235
ASCO 2013: new developments in lung cancer Andreas PircherMichael FieglWolfgang Hilbe short review 26 November 2013 Pages: 236 - 239
ASCO annual meeting 2013: head and neck cancer Georg Pall short review 21 September 2013 Pages: 240 - 243
ASCO 2013—treatment of metastatic melanoma: is it still a story of success? Georg Weinlich short review 23 October 2013 Pages: 244 - 246
Update on neurooncology Annual meeting of the American Society of Clinical Oncology (ASCO) 2013 Silvia HoferChristine Marosi short review 25 September 2013 Pages: 247 - 250
ASCO 2013—new concepts and the path to individualized therapy Heinz Zwierzina comment 10 December 2013 Pages: 251 - 253
Transfusion-associated graft-versus-host disease: an update Christian Dal-PontHarald Schennach short review 23 October 2013 Pages: 254 - 257
The contribution of antibodies to targeted cancer therapy Panagiotis ApostolouIoannis Papasotiriou short review 28 November 2013 Pages: 258 - 261
Targeted delivery of anticancer agents using antibodies as vectors Maria ToloudiIoannis Papasotiriou short review 29 November 2013 Pages: 262 - 266
T-DM1 in breast cancer therapeutics: the first drug of its generation Michalis V Karamouzis review 23 October 2013 Pages: 267 - 270
Targeting AML with anti-CD33 antibodies: historical walkthrough, clinical impact, future directions Spyridon Dimitrios ChondropoulosAnnaliza DelasticAlexandros Spyridonidis short review 10 December 2013 Pages: 271 - 274
Brentuximab vedotin, a highly active ADC as a new therapeutic option for CD30+ lymphomas Sofia Stamatopoulou short review 12 December 2013 Pages: 275 - 277